Trial
NCT06662227
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Early Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Wondercel Biotech (ShenZhen)
Collaborators
—
Condition
B Cell Lymphoma
Intervention
Single dose injection of certain dose of UWD-19
Why stopped
Because the implementation of the new regulation policy by the Chinese authority
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-07